Recurrent Non-Squamous Non-Small Cell Lung Cancer
1 clinical trials · Condition
◉ Watch Recurrent Non-Squamous Non-Small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients (NCT06028633) | Peking University First Hospital | 2023-10-01 |
Track Recurrent Non-Squamous Non-Small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.